PMC:7299399 / 19916-20672 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T92","span":{"begin":80,"end":83},"obj":"Body_part"},{"id":"T93","span":{"begin":642,"end":649},"obj":"Body_part"}],"attributes":[{"id":"A92","pred":"fma_id","subj":"T92","obj":"http://purl.org/sig/ont/fma/fma74412"},{"id":"A93","pred":"fma_id","subj":"T93","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"ntly started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410).\nAnother candidate COVID-19 vaccine for Phase I clinical trial is from the University of Oxford and AstraZeneca (NCT04324606).68 Around 1110 people will take part in the trial, which started recruitment at the end of April 2020. The vaccine is based on a chimpanzee adenovirus vaccine vector (ChAdOx1) and the SARS-CoV-2 spike protein. Chimpanzee adenoviral vectors against different pathogens have been already tested in thousands of subjec"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T72","span":{"begin":334,"end":342},"obj":"Disease"},{"id":"T73","span":{"begin":625,"end":633},"obj":"Disease"}],"attributes":[{"id":"A72","pred":"mondo_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A73","pred":"mondo_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"ntly started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410).\nAnother candidate COVID-19 vaccine for Phase I clinical trial is from the University of Oxford and AstraZeneca (NCT04324606).68 Around 1110 people will take part in the trial, which started recruitment at the end of April 2020. The vaccine is based on a chimpanzee adenovirus vaccine vector (ChAdOx1) and the SARS-CoV-2 spike protein. Chimpanzee adenoviral vectors against different pathogens have been already tested in thousands of subjec"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T197","span":{"begin":78,"end":79},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T198","span":{"begin":137,"end":140},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T199","span":{"begin":178,"end":189},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10141"},{"id":"T200","span":{"begin":203,"end":204},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T201","span":{"begin":263,"end":266},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T202","span":{"begin":283,"end":290},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T203","span":{"begin":294,"end":300},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T204","span":{"begin":568,"end":569},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T205","span":{"begin":570,"end":580},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9598"},{"id":"T206","span":{"begin":651,"end":661},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9598"},{"id":"T207","span":{"begin":727,"end":733},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"ntly started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410).\nAnother candidate COVID-19 vaccine for Phase I clinical trial is from the University of Oxford and AstraZeneca (NCT04324606).68 Around 1110 people will take part in the trial, which started recruitment at the end of April 2020. The vaccine is based on a chimpanzee adenovirus vaccine vector (ChAdOx1) and the SARS-CoV-2 spike protein. Chimpanzee adenoviral vectors against different pathogens have been already tested in thousands of subjec"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T130","span":{"begin":40,"end":42},"obj":"Chemical"},{"id":"T131","span":{"begin":80,"end":83},"obj":"Chemical"},{"id":"T132","span":{"begin":642,"end":649},"obj":"Chemical"}],"attributes":[{"id":"A130","pred":"chebi_id","subj":"T130","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"},{"id":"A131","pred":"chebi_id","subj":"T131","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"},{"id":"A132","pred":"chebi_id","subj":"T132","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"ntly started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410).\nAnother candidate COVID-19 vaccine for Phase I clinical trial is from the University of Oxford and AstraZeneca (NCT04324606).68 Around 1110 people will take part in the trial, which started recruitment at the end of April 2020. The vaccine is based on a chimpanzee adenovirus vaccine vector (ChAdOx1) and the SARS-CoV-2 spike protein. Chimpanzee adenoviral vectors against different pathogens have been already tested in thousands of subjec"}

{"project":"LitCovid-sentences","denotations":[{"id":"T86","span":{"begin":78,"end":315},"obj":"Sentence"},{"id":"T87","span":{"begin":316,"end":543},"obj":"Sentence"},{"id":"T88","span":{"begin":544,"end":650},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ntly started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410).\nAnother candidate COVID-19 vaccine for Phase I clinical trial is from the University of Oxford and AstraZeneca (NCT04324606).68 Around 1110 people will take part in the trial, which started recruitment at the end of April 2020. The vaccine is based on a chimpanzee adenovirus vaccine vector (ChAdOx1) and the SARS-CoV-2 spike protein. Chimpanzee adenoviral vectors against different pathogens have been already tested in thousands of subjec"}

{"project":"LitCovid-PubTator","denotations":[{"id":"284","span":{"begin":32,"end":42},"obj":"Gene"},{"id":"288","span":{"begin":169,"end":173},"obj":"Species"},{"id":"289","span":{"begin":178,"end":189},"obj":"Species"},{"id":"290","span":{"begin":294,"end":300},"obj":"Species"},{"id":"310","span":{"begin":636,"end":641},"obj":"Gene"},{"id":"312","span":{"begin":456,"end":462},"obj":"Species"},{"id":"313","span":{"begin":570,"end":591},"obj":"Species"},{"id":"314","span":{"begin":625,"end":635},"obj":"Species"},{"id":"315","span":{"begin":651,"end":661},"obj":"Species"},{"id":"321","span":{"begin":334,"end":342},"obj":"Disease"}],"attributes":[{"id":"A288","pred":"tao:has_database_id","subj":"288","obj":"Tax:10090"},{"id":"A289","pred":"tao:has_database_id","subj":"289","obj":"Tax:10141"},{"id":"A290","pred":"tao:has_database_id","subj":"290","obj":"Tax:9606"},{"id":"A310","pred":"tao:has_database_id","subj":"310","obj":"Gene:43740568"},{"id":"A312","pred":"tao:has_database_id","subj":"312","obj":"Tax:9606"},{"id":"A313","pred":"tao:has_database_id","subj":"313","obj":"Tax:310542"},{"id":"A314","pred":"tao:has_database_id","subj":"314","obj":"Tax:2697049"},{"id":"A315","pred":"tao:has_database_id","subj":"315","obj":"Tax:9598"},{"id":"A321","pred":"tao:has_database_id","subj":"321","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ntly started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410).\nAnother candidate COVID-19 vaccine for Phase I clinical trial is from the University of Oxford and AstraZeneca (NCT04324606).68 Around 1110 people will take part in the trial, which started recruitment at the end of April 2020. The vaccine is based on a chimpanzee adenovirus vaccine vector (ChAdOx1) and the SARS-CoV-2 spike protein. Chimpanzee adenoviral vectors against different pathogens have been already tested in thousands of subjec"}

{"project":"2_test","denotations":[{"id":"32519842-32433465-158491","span":{"begin":255,"end":257},"obj":"32433465"}],"text":"ntly started the recruitment in Phase I/II trials (NCT04368728, NCT04380701). A DNA plasmid vaccine by Inovio Pharmaceuticals (INO-4800) has showed promising results in mice and guinea pigs according to a recent article published in Nature Communications(67) and has entered Phase I testing in humans (NCT04336410).\nAnother candidate COVID-19 vaccine for Phase I clinical trial is from the University of Oxford and AstraZeneca (NCT04324606).68 Around 1110 people will take part in the trial, which started recruitment at the end of April 2020. The vaccine is based on a chimpanzee adenovirus vaccine vector (ChAdOx1) and the SARS-CoV-2 spike protein. Chimpanzee adenoviral vectors against different pathogens have been already tested in thousands of subjec"}